2269 — WuXi Biologics (Cayman) Share Price
Last trade - 00:00- HK$59.20bn
- HK$55.96bn
- CNY17.03bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.9 | ||
| PEG Ratio (f) | 0.56 | ||
| EPS Growth (f) | 26.79% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.36 | ||
| Price to Tang. Book | 1.43 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.21 | ||
| EV to EBITDA | 8.99 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.85% | ||
| Return on Equity | 9.02% | ||
| Operating Margin | 25.43% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 3,983.69 | 5,612.38 | 10,290.05 | 15,268.66 | 17,034.26 | 18,435.24 | 21,787.65 | 46.38% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +47.33 | +58.17 | +90.81 | +32.28 | -22.68 | +29.88 | +20.83 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.
Directors
- Ge Li NEC (54)
- Zhisheng Chen CEO (48)
- Shaohua Lu-Wong CFO (52)
- Weichang Zhou EVP (57)
- Jijie Gu EVP (55)
- William Aitchison SVP (66)
- Jian Dong SVP (57)
- Keqiang Shen SVP (57)
- Jerry Xu SVP (58)
- Angus Scott Turner VPR (52)
- Yue Huang SEC
- Ying Man Sham SEC
- Yanling Cao NED (37)
- Zhao Ning NED (54)
- Yibing Wu NED
- Kenneth Hitchner NID (61)
- William Keller NID (73)
- Teh-Ming Kwauk NID (68)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 27th, 2014
- Public Since
- June 13th, 2017
- No. of Employees
- 12,740
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 4,259,135,569
- Address
- No. 108, Meiliang Road, Mashan, WUXI
- Web
- https://www.wuxibiologics.com/
- Phone
- Contact
- Eileen Wang
- Auditors
- Deloitte Touche Tohmatsu
Latest News for 2269
Upcoming Events for 2269
WuXi Biologics (Cayman) Inc Annual Shareholders Meeting
WuXi Biologics (Cayman) Inc Annual Shareholders Meeting
Half Year 2024 WuXi Biologics (Cayman) Inc Earnings Release
Similar to 2269
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:24 UTC, shares in WuXi Biologics (Cayman) are trading at HK$13.90. This share price information is delayed by 15 minutes.
Shares in WuXi Biologics (Cayman) last closed at HK$13.90 and the price had moved by -74.19% over the past 365 days. In terms of relative price strength the WuXi Biologics (Cayman) share price has underperformed the FTSE Developed Asia Pacific Index by -74.01% over the past year.
The overall consensus recommendation for WuXi Biologics (Cayman) is Buy. You can view the full broker recommendation list by unlocking its StockReport.
WuXi Biologics (Cayman) does not currently pay a dividend.
WuXi Biologics (Cayman) does not currently pay a dividend.
WuXi Biologics (Cayman) does not currently pay a dividend.
To buy shares in WuXi Biologics (Cayman) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$13.90, shares in WuXi Biologics (Cayman) had a market capitalisation of HK$59.20bn.
Here are the trading details for WuXi Biologics (Cayman):
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2269
Based on an overall assessment of its quality, value and momentum WuXi Biologics (Cayman) is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in WuXi Biologics (Cayman) is HK$31.43. That is 126.13% above the last closing price of HK$13.90.
Analysts covering WuXi Biologics (Cayman) currently have a consensus Earnings Per Share (EPS) forecast of CNY1.02 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like WuXi Biologics (Cayman). Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -74.33%.
As of the last closing price of HK$13.90, shares in WuXi Biologics (Cayman) were trading -59.46% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The WuXi Biologics (Cayman) PE ratio based on its reported earnings over the past 12 months is 11.9. The shares last closed at HK$13.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
WuXi Biologics (Cayman)'s management team is headed by:
- Ge Li - NEC
- Zhisheng Chen - CEO
- Shaohua Lu-Wong - CFO
- Weichang Zhou - EVP
- Jijie Gu - EVP
- William Aitchison - SVP
- Jian Dong - SVP
- Keqiang Shen - SVP
- Jerry Xu - SVP
- Angus Scott Turner - VPR
- Yue Huang - SEC
- Ying Man Sham - SEC
- Yanling Cao - NED
- Zhao Ning - NED
- Yibing Wu - NED
- Kenneth Hitchner - NID
- William Keller - NID
- Teh-Ming Kwauk - NID